Crescent Biopharma Inc (CBIO)

Currency in USD
18.550
-1.420(-7.11%)
Closed·
18.5500.000(0.00%)
·
CBIO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
17.48020.810
52 wk Range
8.72027.500
Key Statistics
Prev. Close
18.55
Open
19.86
Day's Range
17.48-20.81
52 wk Range
8.72-27.5
Volume
416.08K
Average Volume (3m)
255.3K
1-Year Change
-28.5989%
Book Value / Share
5.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CBIO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
30.286
Upside
+63.27%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales decline in the current year

Crescent Biopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

9 Buy
0 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 30.286
(+63.27% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Stifel
Buy30.00+61.73%29.00Maintain30/04/2026
H.C. Wainwright
Buy22.00+18.60%25.00Maintain02/03/2026
Stifel
Buy29.00+56.33%32.00Maintain26/02/2026
Piper Sandler
Buy---New Coverage28/01/2026
Guggenheim
Buy35.00+88.68%-New Coverage21/01/2026

Earnings

Latest Release
26/02/2026
EPS / Forecast
-3.35 / --
Revenue / Forecast
10.84M / --
EPS Revisions
Last 90 days

CBIO Income Statement

Compare CBIO to Peers and Sector

Metrics to compare
CBIO
Peers
Sector
Relationship
P/E Ratio
−3.8x−4.0x−0.5x
PEG Ratio
-−0.060.00
Price/Book
3.4x1.8x2.6x
Price / LTM Sales
51.9x113.5x3.2x
Upside (Analyst Target)
61.7%159.6%55.3%
Fair Value Upside
Unlock0.8%9.7%Unlock

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

Employees
55

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
3.29M9.91%61.11M
Other Institutional Investors
34.70M90.09%643.64M
Public Companies & Retail Investors
0.000.00%0.00
Total
37.99M100.00%704.75M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Fidelity Mt. Vernon Street Trust - Fidelity Growth Company Fund2.83%939,51817,428
Vanguard Index Funds - Vanguard Total Stock Market ETF2.10%698,84612,964

People Also Watch

10.270
ERAS
+0.39%
58.340
ORKA
-5.80%
20.63
TNGX
+0.34%
78.75
APGE
-2.95%

FAQ

What Is the Crescent Biopharma (CBIO) Stock Price Today?

The Crescent Biopharma stock price today is 18.550 USD.

What Stock Exchange Does Crescent Biopharma Trade On?

Crescent Biopharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Crescent Biopharma?

The stock symbol for Crescent Biopharma is "CBIO."

What Is the Crescent Biopharma Market Cap?

As of today, Crescent Biopharma market cap is 616.400M USD.

What Is Crescent Biopharma's Earnings Per Share (TTM)?

The Crescent Biopharma EPS (TTM) is -8.047.

From a Technical Analysis Perspective, Is CBIO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Crescent Biopharma Stock Split?

Crescent Biopharma has split 1 times.

How Many Employees Does Crescent Biopharma Have?

Crescent Biopharma has 55 employees.

What is the current trading status of Crescent Biopharma (CBIO)?

As of 19/05/2026, Crescent Biopharma (CBIO) is trading at a price of 18.550 USD, with a previous close of 18.550 USD. The stock has fluctuated within a day range of 17.480 USD to 20.810 USD, while its 52-week range spans from 8.720 USD to 27.500 USD.

What Is Crescent Biopharma (CBIO) Price Target According to Analysts?

The average 12-month price target for Crescent Biopharma is 30.286 USD, with a high estimate of 35 USD and a low estimate of 22 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +63.27% Upside potential.

What Is the CBIO Premarket Price?

CBIO's last pre-market stock price is 20.360 USD. The pre-market share volume is 10.000, and the stock has decreased by 0.390, or 1.950%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.